Melanie Ivarsson
Corporate Officer/Principal at MODERNA, INC.
Profile
Melanie Ivarsson is currently the Director at Loqus23 Therapeutics Ltd.
and the Chief Development Officer at Moderna, Inc. Previously, she worked as the Vice President & Head-Global Clinical Operations at Takeda Pharmaceuticals U.S.A., Inc. Dr. Ivarsson holds a doctorate from the University of Bristol and an MBA from MIT Sloan School of Management.
Melanie Ivarsson active positions
Companies | Position | Start |
---|---|---|
MODERNA, INC. | Corporate Officer/Principal | 2020-01-29 |
Loqus23 Therapeutics Ltd.
Loqus23 Therapeutics Ltd. BiotechnologyHealth Technology Loqus23 Therapeutics Ltd.engages in research and development of biotechnology. The company was founded on March 29, 2019 and is headquartered in in Reading, the United Kingdom. | Director/Board Member | 2022-01-24 |
Former positions of Melanie Ivarsson
Companies | Position | End |
---|---|---|
Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Corporate Officer/Principal | - |
Training of Melanie Ivarsson
University of Bristol | Doctorate Degree |
MIT Sloan School of Management | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
MODERNA, INC. | Health Technology |
Private companies | 2 |
---|---|
Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Health Technology |
Loqus23 Therapeutics Ltd.
Loqus23 Therapeutics Ltd. BiotechnologyHealth Technology Loqus23 Therapeutics Ltd.engages in research and development of biotechnology. The company was founded on March 29, 2019 and is headquartered in in Reading, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Melanie Ivarsson